Abstract
Compared to cellular immunotherapy, engineering macrophage-derived EVs which carry nanoparticles, drugs, proteins, nucleic acids etc. can target tumor cells to improve biosafety and treatment efficacy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
